Intec Pharma (NTEC) Earns Coverage Optimism Rating of 0.07

News articles about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intec Pharma earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7452210332254 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Several equities analysts have commented on NTEC shares. Roth Capital set a $10.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a research note on Thursday, August 10th. Maxim Group set a $9.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, May 24th. Zacks Investment Research lowered shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 24th. Finally, ValuEngine lowered shares of Intec Pharma from a “hold” rating to a “sell” rating in a research note on Friday, June 9th.

Shares of Intec Pharma (NASDAQ NTEC) traded up 1.32% during trading on Wednesday, hitting $7.65. 37,516 shares of the stock were exchanged. The stock’s market cap is $105.10 million. The stock’s 50 day moving average price is $7.47 and its 200 day moving average price is $5.30. Intec Pharma has a one year low of $4.20 and a one year high of $7.89.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/09/13/intec-pharma-ntec-earns-coverage-optimism-rating-of-0-07.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply